Synbio Technologies is a U.S.-based synthetic biology and biotechnology company, founded in 2013 and headquartered in Monmouth Junction, New Jersey, United States. The company specializes in providing advanced DNA synthesis, gene engineering, and molecular biology services to support research and innovation in life sciences, precision medicine, diagnostics, and biotechnology.
Built by a team of experienced synthetic biologists, Synbio Technologies delivers high-precision and cost-effective solutions for researchers worldwide — from custom DNA and gene synthesis to oligonucleotide production, RNA synthesis, plasmid construction, and protein expression. Its services help accelerate workflows in areas such as diagnostic reagent development, antibody discovery, vaccine research, and metabolic engineering.
Using state-of-the-art technology platforms, proprietary bioinformatics, and stringent quality standards (including ISO-certified manufacturing), Synbio Technologies aims to empower scientific discovery and innovation by providing reliable and scalable synthetic biology tools and services.
With a global customer base and a full suite of molecular biology capabilities — including high-throughput DNA synthesis, CRISPR library construction, and protein expression and purification — Synbio Technologies supports academic, industrial, and clinical research teams in accelerating breakthroughs across life science disciplines.